What is the price of trametinib targeted drug?

Trametinib, trade nameMekinist, is an oral targeted drug approved by the US FDA on May 29, 2013 and developed by GlaxoSmithKline (GSK). Trametinib is mainly used to treat unresectable or metastatic melanoma with BRAF V600E or V600K mutations. It should be noted that patients who have received BRAF inhibitor treatment are not suitable.

As a reversible inhibitor ofMEK 1/2, trametinib affects the MAPK pathway through its effect on MEK protein, thereby inhibiting cell proliferation. Trametinib is an oral drug, and the dosage needs to be determined according to the doctor's recommendation and the patient's condition.

Today, trametinib has become a member of my country's medical insurance catalog. Trametinib on the domestic market is an original drug with a specification of 2mg*30 tablets/box, and the price after medical insurance reimbursement is less than 12,000 yuan. At the same time, we also learned that related generic drugs of trametinib have been launched in overseas markets. These generic drugs are produced and sold by multiple pharmaceutical manufacturers in Laos. Their specifications are also 2mg*30 tablets, but the price is only about 1,900 yuan. According to patient feedback, the effect of generic trametinib is also quite good, so patients can choose the drug that suits them based on their actual situation. If you have any questions about the use or purchase of trametinib, it is recommended to consult a regular overseas medical consultant.

In general, trametinib provides a new treatment option for BRAF V600 mutation-positive melanoma patients, and its clinical application brings hope to these patients.